Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class IIOngoingMar 12, 2025Nelarabine InjectionFailed Impurities/Degradation SpecificationsZydus Pharmaceuticals (USA) Inc · D-0256-2025Class IIOngoingMar 12, 2025Nelarabine InjectionFailed Impurities/Degradation SpecificationsZydus Pharmaceuticals (USA) Inc · D-0255-2025Class IIOngoingMar 12, 2025Morphine Sulfate 5 mg per 0.25 mL Oral SyringeDefective Delivery System: Leakage observed after oral solution was repackaged into unit-dose syringes.Safecor Health, LLC · D-0254-2025Class IIOngoingMar 12, 2025Lorazepam 0.5 mg per 0.25 mL Oral SyringeDefective Delivery System: Leakage observed after oral solution was repackaged into unit-dose syringes.Safecor Health, LLC · D-0253-2025Class IIOngoingMar 12, 2025Ferrous Sulfate 7.5 mg Iron/0.5 mL Oral SyringeDefective Delivery System: Leakage observed after oral solution was repackaged into unit-dose syringes.Safecor Health, LLC · D-0252-2025Class IIOngoingMar 12, 2025Simethicone 20 mg per 0.3 mL Oral SyringeDefective Delivery System: Leakage observed after oral solution was repackaged into unit-dose syringes.Safecor Health, LLC · D-0251-2025Class IIOngoingMar 12, 2025Ergocalciferol - Vitamin D Supplement - 10 mcgDefective Delivery System: Leakage observed after oral solution was repackaged into unit-dose syringes.Safecor Health, LLC · D-0250-2025Class IIOngoingMar 12, 2025Morphine Sulfate Extended-Release TabletsFailed Dissolution SpecificationsSun Pharmaceutical Industries Inc · D-0249-2025Class IITerminatedMar 5, 2025Avastin 1.25 mg/0.05 mL in 0.25 mL SyringeLack of Assurance of Sterility: due to a quality control process deviationTurbare Manufacturing · D-0248-2025Class IIOngoingMar 5, 2025ViaMed Alcohol Prep PadsLack of assurance of sterility and cGMP deviations observed at the manufacturing site.Wuxi Medical lnstrument Factory Co., Ltd. · D-0247-2025Class IICompletedMar 5, 2025Estradiol GelDefective Container: Some packets may not be fully sealed, potentially allowing for loss of Ethanol from the product.Padagis US LLC · D-0246-2025Class IOngoingFeb 26, 2025Fentanyl Transdermal System CIIDefective delivery system - patches could be multi-stacked, adhered one on top of the other, in a single product pouch.Alvogen, Inc · D-0245-2025Class IIOngoingFeb 26, 2025Atomoxetine CapsulesCGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.Glenmark Pharmaceuticals Inc., USA · D-0244-2025Class IIOngoingFeb 26, 2025Atomoxetine CapsulesCGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.Glenmark Pharmaceuticals Inc., USA · D-0243-2025Class IIOngoingFeb 26, 2025Atomoxetine CapsulesCGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.Glenmark Pharmaceuticals Inc., USA · D-0242-2025Class IIOngoingFeb 26, 2025Atomoxetine CapsulesCGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.Glenmark Pharmaceuticals Inc., USA · D-0241-2025Class IIOngoingFeb 26, 2025Atomoxetine CapsulesCGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.Glenmark Pharmaceuticals Inc., USA · D-0240-2025Class IIOngoingFeb 26, 2025Atomoxetine CapsulesCGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.Glenmark Pharmaceuticals Inc., USA · D-0239-2025Class IIOngoingFeb 26, 2025Atomoxetine CapsulesCGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.Glenmark Pharmaceuticals Inc., USA · D-0238-2025Class IIOngoingFeb 26, 2025Atomoxetine CapsulesCGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.Glenmark Pharmaceuticals Inc., USA · D-0237-2025Class IIOngoingFeb 26, 2025Atomoxetine CapsulesCGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.Glenmark Pharmaceuticals Inc., USA · D-0236-2025Class IIOngoingFeb 26, 2025Atomoxetine CapsulesCGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.Glenmark Pharmaceuticals Inc., USA · D-0235-2025Class IIOngoingFeb 26, 2025Atomoxetine CapsulesCGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.Glenmark Pharmaceuticals Inc., USA · D-0234-2025Class IIOngoingFeb 26, 2025Atomoxetine CapsulesCGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.Glenmark Pharmaceuticals Inc., USA · D-0233-2025Class IIOngoingFeb 26, 2025Atomoxetine CapsulesCGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.Glenmark Pharmaceuticals Inc., USA · D-0232-2025Class IIOngoingFeb 26, 2025Atomoxetine CapsulesCGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.Glenmark Pharmaceuticals Inc., USA · D-0231-2025Class IOngoingFeb 26, 2025Phenylephrine HCl InjectionPresence of Particulate Matter.Provepharm Inc. · D-0230-2025Class IIOngoingFeb 26, 2025Silodosin CapsulesSubpotent Drug: Out of Specification (OOS) result for De hydro Impurity (0.654%) for 18 M Stability sample and low assay 94.9% (specification of NLT 95.0% NMT 105%)AvKARE · D-0229-2025Class IIOngoingFeb 26, 2025Lorazepam TabletsFailed impurities/degradation specifications and Sub-potent Drug: Out-of-specification results were obtained during routine stability testing for Assay and Impurities.The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories · D-0228-2025Class IIOngoingFeb 26, 2025Lorazepam TabletsFailed impurities/degradation specifications and Sub-potent Drug: Out-of-specification results were obtained during routine stability testing for Assay and Impurities.The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories · D-0227-2025Class IIOngoingFeb 26, 2025Lorazepam TabletsFailed impurities/degradation specifications and Sub-potent Drug: Out-of-specification results were obtained during routine stability testing for Assay and Impurities.The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories · D-0226-2025Class IICompletedFeb 26, 2025fentaNYL Citrate In Sodium Chloride 1600mcg/100mLLack of Assurance of SterilityFagron Compounding Services · D-0225-2025Class IIOngoingFeb 19, 2025Irbesartan Tablets USPOut of Specification for DissolutionAvKARE · D-0224-2025Class IOngoingFeb 12, 2025Adrenalin Chloride SolutionLabeling: Not Elsewhere Classified: misleading label similar in appearance to the FDA-approved drug product Adrenalin¿ (epinephrine injection, USP)ENDO USA, Inc. · D-0223-2025Class IIITerminatedFeb 12, 2025Guaifenesin and Codeine Phosphate Oral Solution USPSuperpotent; sodium benzoate preservativePAI Holdings, LLC. dba Pharmaceutical Associates Inc · D-0222-2025Class IIOngoingFeb 12, 2025Potassium Chloride Extended-Release TabletsFailed Dissolution Specifications.The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories · D-0221-2025Class IIOngoingFeb 12, 2025HydrALAZINE HydrochlorideFailed Impurities/Degradation SpecificationsSky Packaging · D-0220-2025Class IIOngoingFeb 12, 2025HydrALAZINE HydrochlorideFailed Impurities/Degradation SpecificationsSky Packaging · D-0219-2025Class IIOngoingFeb 12, 2025Granix (tbo-filgrastim) Injection 300 mcg/0.5 mLFailed Stability Specifications - 12-month stability test result for one of the known peptides is below the specification limitTeva Pharmaceuticals USA, Inc · D-0218-2025Class IITerminatedFeb 12, 2025Carvedilol 25 mg TabletCGMP deviations: presence of N-Nitroso Carvedilol Impurity-1 (NNC 1), above the FDA recommended acceptable intake limit.RemedyRepack Inc. · D-0217-2025